CVS Stock Has Left Its Peers Behind. Or Has It?
The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.
CVS Health (CVS) is a fixture of American life, a sprawling enterprise that combines a health insurer, a pharmacy benefit manager, and nearly nine thousand retail pharmacies. After a year that saw its stock return +38%, outperforming the S&P 500, investors have clearly been pleased. But a closer look at its competitive standing reveals a sharp disconnect. The stock’s performance ranks first among its peers, yet its core financial metrics like growth and profitability sit squarely in the middle of the pack. Has the stock’s powerful run gotten ahead of the business reality, or is the market correctly pricing in a fundamental shift the numbers have yet to reflect?
How does CVS’s performance stack up against its rivals?
The numbers lay the mismatch bare. While CVS delivered the group’s best one-year stock return, its operating margin of 3.4% trails peers like UnitedHealth, which posted a 4.8% margin. Its 7.4% revenue growth is solid, but it’s not a runaway success; Cigna grew slightly faster at 7.7% yet saw its stock deliver a -3.8% return over the same period. This isn’t a case of a leading operator earning a premium. Instead, investors have rewarded CVS with a chart-topping return for a second- or third-place operational finish.
Valuation makes the mismatch even starker: at 25.5 times earnings, CVS actually commands a premium over both UnitedHealth (25.3x) and Cigna (11.6x), despite lagging on operating margin. The market isn’t paying a premium for CVS’s current results; it’s the stock’s recent momentum that stands apart from the fundamentals.
| CVS | UNH | CI | WMT | |
|---|---|---|---|---|
| Market Cap ($ Bil) | 124.8 | 357.5 | 74.4 | 842.5 |
| PE Ratio | 25.5 | 25.3 | 11.6 | 38.2 |
| LTM Revenue Growth | 7.4% | 6.5% | 7.7% | 6.2% |
| LTM Operating Margin | 3.4% | 4.8% | 3.2% | 4.4% |
| 12M Stock Return | 38% | 31% | -3.8% | 10.1% |
Is the Aetna turnaround strong enough to offset new PBM pressures?
The market’s enthusiasm is rooted in tangible progress, particularly within the company’s Aetna insurance division. Management highlighted that so far this year, it has “delivered more than $2 billion of year-over-year improvement in adjusted operating income” in that business. This execution success led the company to raise its full-year 2026 adjusted EPS guidance to a range of $7.90 to $8.10. This progress has investors wondering about the stock’s future.
But here is the catch: while Aetna is firing on all cylinders, management is already flagging trouble for 2027 in another core division. They explicitly stated, “we believe we will see membership declines in Caremark next year,” referring to their large pharmacy benefit management (PBM) business. This isn’t a vague worry; it’s a specific warning about losing customers, driven by a “deliberate approach to our client renewals” and market exits by some health plan clients. The market seems to be rewarding the strong Aetna recovery while looking past the projected customer attrition in the PBM business, which poses a tangible headwind to segment earnings.
For investors who prefer to bet on the entire sector’s evolution rather than a single company’s complex story, a U.S. healthcare providers ETF offers broader exposure to the industry.
What number will prove whether the stock’s run was justified?
The debate boils down to whether the momentum in the insurance and retail pharmacy businesses can overpower the acknowledged weakness coming in the PBM segment. For now, the market is betting it can. The company’s ability to generate cash remains strong, with guidance for cash flow from operations updated to “at least $11.5 billion” for the full year.
The ultimate test, however, will be next year’s earnings. Despite flagging the Caremark pressures, management provided a preliminary outlook for 2027, stating that adjusted EPS of “at least $8.44” appears “reasonable at this juncture”—representing roughly 13% growth off an adjusted 2026 baseline of $7.46, which excludes prior-year development. Hitting or exceeding that specific number, in the face of known membership losses, will be the clearest sign of whether the company’s enterprise-wide strength is enough to justify the stock’s number-one ranking.
This piece pulled one thread; our full peer-by-peer dashboards for CVS lay every metric side by side, updated daily.
Prefer the theme to this single name? A U.S. healthcare providers ETF like IHF holds the sector rather than this one name. That way no single company’s next surprise decides the outcome.
The best stock in the group is still a single stock
Ranking a company against its peers sharpens the picture, and whichever name wins is still a single stock. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.